ABN
Advanced BioNutrition Corp

7155 Columbia Gateway Drive, Suite H • Columbia, MD 21046
Local: 410-730-8600 • Fax: 410-730-9311 • www.abn-corp.com

Two Join Advanced BioNutrition Board 8/7/2012

Two Join Advanced BioNutrition Board

 

Two Join Advanced BioNutrition Corp Board
 
            Columbia, MD—August 07, 2012—Advanced BioNutrition Corp (ABN), a technology provider focused on offering environmentally sustainable and science-based technology solutions to the nutrition and health industries, announces the addition of Dr. Neil Cameron and Dr. Sven Harmsen to its Board of Directors.
             “The extensive experience and expertise in collaborative business development, research, and technology that Dr. Cameron and Dr. Harmsen bring to ABN’s board will help direct and strengthen our company’s ability to develop and commercialize innovative products and technologies that better stabilize, protect, and deliver bioactives to their targeted sites,” said William F. Kirk, ABN chairman and CEO.
            Cameron, investment director for Emerald Technology Ventures, specializes in the field of advanced materials and processes. Prior to joining Emerald in 2006, he served as project leader and staff scientist with the National Research Council of Canada (Industrial Materials Institute) and was a research associate at McGill University. Recent projects have included work in nanotechnology, high-fidelity micro- and nanofabrication, and polymer synthesis. Cameron earned his Doctorate in Chemistry from McGill University, in Montreal, Canada, and holds a Bachelor of Science in Chemistry and Biochemistry from the University of King’s College (Dalhousie University), in Halifax, Nova Scotia.
             “ABN’s patent-protected approach to solving delivery issues in the animal-health, nutriceutical, and agricultural markets provides compelling economics for all parties, as validated in commercial and pre-commercial agreements with multinational customers like CentroVet (Chile), Chr Hansen (Denmark) and many others. Emerald is delighted to assist and participate in the growth of this portfolio company,” said Cameron.
            Harmsen currently serves as investment manager in BASF’s corporate venture arm, BASF Venture Capital (BVC). In this role he is responsible for strategic investments in innovative technology companies with a geographic focus on the eastern half of North America. Before taking over this position, he was global head of new business development for the agrochemicals division of BASF SE in Limburgerhof, Germany, where he was responsible for identifying new markets to commercialize certain technologies and to scout for new technologies. Earlier in his career, 4SC AG, in Martinsried, Germany, employed Harmsen where he served first as head of medicinal chemistry then as manager of business development, with responsibility for forming international technology collaborations with pharmaceutical companies. Harmsen started his industrial career doing cardiovascular research with Hoechst Marion Roussel (now Sanofi), and Hoechst Schering AgrEvo (now Bayer CropScience). After receiving his diploma in chemistry, Harmsen received his Ph.D. from Julius Maximilians University in Wurzburg, Germany, working on stereoselective total syntheses of bioactive natural products. Harmsen completed his post-doctoral research at Stanford University.
            "ABN deserves the long term commitment BASF Venture Capital shows with its investment. We are glad to have ABN in our portfolio and believe in the continuous success of its innovative technology," said Harmsen.
            Advanced BioNutrition Corporation (www.advancedbionutrition.com), Columbia, MD USA, is a privately-held research and development company. Its scientists work alongside customers, using a collaborative approach focused on adapting ABN’s proprietary technologies to resolve specific product issues and formulation challenges to better protect, stabilize, and/or deliver sensitive bioactives. ABN is continually creating a portfolio of technologies that can be customized for use in industrial, human, plant, and animal applications, including animal health oral vaccines, carotenoids, human and animal dietary supplements, gastric protection, agricultural inoculants, and invasive species management. All of ABN’s technologies employ patented and patent-pending embedding processes using materials acceptable for customers’ stewardship and regulatory needs.
 
# # #
08/07/2012

 

 Business Solutions provided by ByteRightSupport